. 2022 Jul 22;199(5):665–678. doi: 10.1111/bjh.18370

TABLE 1.

Suggested investigations at diagnosis of BP‐CML and to monitor response to therapy

	Diagnosis	On therapy
Full blood count, blood film and 200‐cell differential	X	X
Immunophenotyping by multi‐parameter flow cytometry	X	X ^a
Cytogenetics for full karyotype	X	X ^a
BCR‐ABL qRT‐PCR^IS	X	X ^b
BCR‐ABL kinase domain mutation testing by NGS	X	X ^c
NGS myeloid/lymphoid panel assessment	X
Tissue typing of patient, siblings and VUD search if transplant being considered	X
Lumbar puncture and CSF cytology in lymphoid and mixed phenotype BP	X	X ^d

Abbreviations: CSF, cerebrospinal fluid; IS, International Scale; MMR, major molecular remission; NGS, next generation sequencing; VUD, volunteer unrelated donor.

^{^a}

Bone marrow assessment three‐monthly until achievement of MMR and then as clinically indicated.

^{^b}

Three‐monthly indefinitely. More frequent monitoring may be required if concerned about relapse of losing molecular response.

^{^c}

Three‐monthly until achievement of MMR and then if loss of response.

^{^d}

To correspond with intrathecal therapy and as clinically indicated.